A comparison of real-world data with a single-arm trial of Ceralasertib plus Paclitaxel in patients with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies
Latest Information Update: 02 Aug 2021
At a glance
- Drugs Ceralasertib (Primary) ; Antineoplastics; Cabazitaxel; Dacarbazine; Docetaxel; Fotemustine; Paclitaxel; Taxanes; Temozolomide
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Aug 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology